This is well aligned with previous reports describing the role of NF-κB activity and IκBα degradation in the pathogenesis of NAFLD and the beneficial role of AICAR in downregulating the NF-κB pathway [39,40]. Here, NFKBIA is linked to metabolic dysfunction-associated steatotic liver disease.